Decreased heme levels result in improved mitochondrial function and decreased FAS with an overall reduction in NOV-inflammation, fibrosis, and NASH scores (summarized in Figure 8). The gene discussed is FAS; the disease is metabolic dysfunction-associated steatohepatitis.